Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 76-85

  Schilder, Christina M ^a,e   Eggens, Petronella C ^a   Seynaeve, Caroline ^b   Linn, Sabine C ^a   Boogerd, Willem ^a,c   Gundy, Chad M ^a   Beex, Louk V ^d   Van Dam, Frits S ^a   Schagen, Sanne B ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Slotervaart Medical Center   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EXEMESTANE; TAMOXIFEN;

ANOREXIA; ANXIETY; ANXIETY DISORDER; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIARRHEA; DYSPNEA; DYSTHYMIA; FATIGUE; FEMALE; HORMONAL THERAPY; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEMORY DISORDER; MENOPAUSAL SYNDROME; MOTOR PERFORMANCE; NAUSEA AND VOMITING; NEUROPSYCHOLOGICAL TEST; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SIDE EFFECT; SLEEP DISORDER; VERBAL BEHAVIOR;

AGED; ANDROSTADIENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANXIETY; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; CYCLOPHOSPHAMIDE; DEPRESSION; DOXORUBICIN; FATIGUE; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY OF LIFE; TAMOXIFEN;

EID: 58149099549     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802314738     Document Type: Article

References (30)

1. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006;20:76-89.
2. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-9.
3. Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-50.
4. Tralongo P, Di Mari A, Ferrau' F. Cognitive impairment, aromatase inhibitors, and age. J Clin Oncol 2005;23:42-43.
5. Schilder CM, Schagen SB. Effects of hormonal therapy on cognitive functioning in breast cancer patients: A review of the literature. Minerva Ginecol 2007;59:387-401.
6. Wise PM. Estrogen therapy: Does it help or hurt the adult and aging brain? Insights derived from animal models. Neuroscience 2006;138:831-5.
7. Chen D, Wu CF, Shi B, Xu YM. Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav 2002;71:269-76.
8. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004;26:955-69.
9. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000;64:165-76.
10. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen-and tamoxifen-associated effects on brain structure and function. Neuroimage 2004;21:364-71.
11. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J,Walot I, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002;94:592-7.
12. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004;13:61-6.
13. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, et al. Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 2007;14:995-8.
14. Meulen EF, Schmand B, van Campen JP, de Koning SJ, Ponds RW, Scheltens P, et al. The seven minute screen: A neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004;75:700-5.
15. Van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-8.
16. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982;21(Pt 1):1-16.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
18. Frojdh K, Hakansson A, Karlsson I. The Hopkins Symptom Checklist-25 is a sensitive case-finder of clinically important depressive states in elderly people in primary care. Int J Geriatr Psychiatry 2004;19:386-90.
19. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-25.
20. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 1999;55:189-99.
21. van den Burg W, Saan RJ, Deelman BG. 15-woordentest. Provisional Manual. Groningen: University Hospital, Department of Neuropsychology; 1985.
22. Wechsler D. Wechsler Memory Scale: Revised. New York: Psychological Corporation; 1987.
23. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002;73:126-33.
24. Wechsler D. WAIS-III Nederlandstalige Bewerking. Technische Handleiding. Lisse: Swets & Zeitlinger; 2000.
25. Hammes J. De Stroop kleur-woord test. Handleiding. Lisse: Swets & Zeitlinger; 1978.
26. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271-6.
27. Alpherts W, Aldenkamp AP. FePsy: The iron psyche. Heemstede: Instituut voor Epilepsiebestrijding; 1994.
28. Lezak M. Neuropsychological assessment. New York: Oxford University Press; 2004.
29. Van der Elst W, van Boxtel MP, Van Breukelen GJ, Jolles J. Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006;12:80-9.
30. Schmand B, Lindeboom J, van Harskamp F. De Nederlandse Leestest voor Volwassenen. Lisse: Swets & Zeitlinger; 1992.